{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:13:58Z","timestamp":1791310438373,"version":"4.3.1"},"reference-count":112,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T00:00:00Z","timestamp":1329264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Thrombotic adverse events (AEs) after clotting factor concentrate administration are rare but the actual rate is unknown. A systematic review of prospective studies (1990\u20132011) reporting safety data of factor concentrates in patients with haemophilia A (HA), haemophilia B (HB) and von Willebrand disease (VWD) was conducted to identify the incidence and type of thrombotic AEs. In 71 studies (45 in HA, 15 HB, 11 VWD) enrolling 5528 patients treated with 27 different concentrates (20 plasma\u2010derived, 7 recombinant), 20 thrombotic AEs (2 HA, 11 HB, 7 VWD) were reported, including two major venous thromboembolic episodes (both in VWD patients on prolonged replacement for surgery). The remaining thrombotic AEs were superficial thrombophlebitis, mostly occurring at infusion sites in surgical patients and\/or during concentrate continuous infusion. The overall prevalence was 3.6 per 10<jats:sup>3<\/jats:sup> patients (3.6 per 10<jats:sup>4<\/jats:sup> for severe AEs) and 1.13 per 10<jats:sup>5<\/jats:sup> infusions, with higher figures in VWD than in haemophilia. Thrombotic AEs accounted for 1.9% of non\u2010inhibitor\u2010related AEs. Thrombosis\u2010related complications occurred in 10.8% of patients with central venous access devices (CVADs) reported in six studies, the risk increasing with time of CVAD use. Data from prospective studies over the last 20\u2003years suggest that the risk of thrombotic AEs from factor concentrate administration is small and mainly represented by superficial thrombophlebitis. These findings support the high degree of safety of products currently used for replacement treatment.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2012.02758.x","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T04:52:25Z","timestamp":1329367945000},"source":"Crossref","is-referenced-by-count":100,"title":["Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies"],"prefix":"10.1111","volume":"18","author":[{"given":"A.","family":"COPPOLA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"FRANCHINI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"MAKRIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"SANTAGOSTINO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"DI MINNO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. M.","family":"MANNUCCI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,15]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01695.x"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00361.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106073442307"},{"key":"e_1_2_8_5_2","first-page":"117","article-title":"Evidence\u2010based recommendations on the treatment of von Willebrand disease in Italy","volume":"7","author":"Mannucci PM","year":"2009","journal-title":"Blood Transfus"},{"key":"e_1_2_8_6_2","volume-title":"Registry of clotting Factor Concentrates","author":"Brooker M","year":"2008"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.203"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01708.x"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02188.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1255445"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03899.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000204020"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00944.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000093642"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-005-2227-3"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-006-6556-7"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613227"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613225"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90166-3"},{"key":"e_1_2_8_20_2","unstructured":"European Commission.Directive 2001\/20\/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Available athttp:\/\/europa.eu.int\/eurlex\/pri\/en\/oj\/dat\/2001\/l_121\/l_12120010501en00340044.pdf2004. Accessed November 6 2011."},{"issue":"2","key":"e_1_2_8_21_2","first-page":"1","article-title":"Viral safety and inhibitor development associated with factor VIIIC ultra\u2010purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates","volume":"27","author":"Lusher JM","year":"1990","journal-title":"Semin Hematol"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199012273232604"},{"key":"e_1_2_8_23_2","first-page":"2428","article-title":"A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients","volume":"83","author":"Bray GL","year":"1994","journal-title":"Blood"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1665410"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656030"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00191.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613925"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00432.x"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00407.x"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00511.x"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2001.00131.x"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00708.x"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02983823"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00730.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7933.2004.00646.x"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00932.x"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00947.x"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01131.x"},{"key":"e_1_2_8_39_2","first-page":"457","article-title":"Full\u2010length sucrose\u2010formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation","volume":"3","author":"Kreuz W","year":"2005","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01217.x"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01416.x"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01472.x"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01412.x"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01554.x"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03032.x"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-12-0724"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-06-0409"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-02-0117"},{"key":"e_1_2_8_50_2","first-page":"32","article-title":"Clinical safety surveillance study of the safety and efficacy of long\u2010term home treatment with ReFacto utilizing a computer\u2010aided diary: a Nordic multicentre study","volume":"100","author":"Petrini P","year":"2009","journal-title":"Haemophilia"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02024.x"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02027.x"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02079.x"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01978.x"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02332.x"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03650.x"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02113.x"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02239.x"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02446.x"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04214.x"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02600.x"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02428.x"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.11.030"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02395.x"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02441.x"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830400310"},{"key":"e_1_2_8_67_2","doi-asserted-by":"crossref","unstructured":"WhiteGCII.Safety and recovery of Mononine in multiple\u2010dose high\u2010dose regimens.1995.","DOI":"10.1159\/000204031"},{"key":"e_1_2_8_68_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1650217"},{"key":"e_1_2_8_69_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3600"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00587.x"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613022"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00721.x"},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2283"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01160.x"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01458.x"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02090.x"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02162.x"},{"key":"e_1_2_8_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02624.x"},{"key":"e_1_2_8_79_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02470.x"},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02453.x"},{"key":"e_1_2_8_81_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00673.x"},{"key":"e_1_2_8_82_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.2.450"},{"key":"e_1_2_8_83_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-27822"},{"key":"e_1_2_8_84_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00809.x"},{"key":"e_1_2_8_85_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1160\/TH04-02-0107","article-title":"In vitro studies, pharmacokinetic studies and clincal use of a high purity double virus inactivated FVIII\/VWF concentrate (Immunate) in the treatment of von Willebrand disease","volume":"92","author":"Ver Elst KMM","year":"2004","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01570.x"},{"key":"e_1_2_8_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02588.x"},{"key":"e_1_2_8_88_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02562.x"},{"key":"e_1_2_8_89_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01901.x"},{"key":"e_1_2_8_90_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02206.x"},{"key":"e_1_2_8_91_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-10-0631"},{"key":"e_1_2_8_92_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.00134.x"},{"key":"e_1_2_8_93_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1727"},{"key":"e_1_2_8_94_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00793.x"},{"key":"e_1_2_8_95_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00724.x"},{"key":"e_1_2_8_96_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00653.x"},{"key":"e_1_2_8_97_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07087.x"},{"key":"e_1_2_8_98_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00780.x"},{"key":"e_1_2_8_99_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01829.x"},{"key":"e_1_2_8_100_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01594.x"},{"key":"e_1_2_8_101_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1248728"},{"key":"e_1_2_8_102_2","first-page":"186","article-title":"Atherothrombosis in von Willebrand disease: an analysis of the literature and implications for clinical management","volume":"38","author":"Franchini M","year":"2012","journal-title":"Semin Thromb Haemost"},{"key":"e_1_2_8_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90206-Q"},{"key":"e_1_2_8_104_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00366.x"},{"key":"e_1_2_8_105_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-008-0253-7"},{"key":"e_1_2_8_106_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06703.x"},{"key":"e_1_2_8_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(10)70150-X"},{"key":"e_1_2_8_108_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.01987.x"},{"key":"e_1_2_8_109_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08005.x"},{"key":"e_1_2_8_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90108-8"},{"key":"e_1_2_8_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90109-X"},{"key":"e_1_2_8_112_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302183280701"},{"key":"e_1_2_8_113_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00909.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2012.02758.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2012.02758.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T17:32:22Z","timestamp":1698687142000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2012.02758.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,15]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1111\/j.1365-2516.2012.02758.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2012.02758.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,15]]}}}